EAHP COVID-19 Resource Centre

The novel coronavirus is rapidly spreading across Europe. Healthcare professionals, such as hospital pharmacists, need to be provided with up-to-date information to adequately manage the situation. EAHP has collected resources that can be used by hospital pharmacists and other healthcare professionals. These range from information provided by specialised agencies, such as the World Health Organisation (WHO) or the European Centre for Disease Prevention and Control (ECDC), to information shared by governments and professional societies in different countries.

Useful resources can be submitted to EAHP via the following email address: covid19[at]eahp[dot]eu 
Materials in native languages can be submitted. They should, however, be accompanied by a short English description and a translation of the name of the document into English.

Advice for healthcare professionals and scientists provided by specialised agencies

World Health Organisation (WHO)

WHO has published an array of information about COVID-19 on its WEBSITE. Information about the outbreak includes but is not limited to country & technical guidance, advice for the public, situation reports and details on global research efforts.

For healthcare professionals the following was made available:

  • Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance
    This document is intended for clinicians involved in the care of adult, pregnant, and paediatric patients with or at risk for severe acute respiratory infection (SARI) when infection with the COVID-19 virus is suspected. Considerations for paediatric patients and pregnant women are highlighted throughout the text. The document is not meant to replace clinical judgment or specialist consultation but rather to strengthen clinical management of these patients and to provide up-to-date guidance. Best practices for infection prevention and control, triage and optimized supportive care are included.

European Centre for Disease Prevention and Control (ECDC)

ECDC is monitoring the rapidly evolving COVID-19 pandemic. Risk assessments, public health guidance and advice on response activities have been provided by the agency. Situation updates, including information on the epidemiological curve and the global distribution, are made available daily via the following LINK.

The following materials have been shared by ECDC on its website:

The following infographics and brochures can be downloaded from ECDC's website for distribution:

A series of micro learning activities related to COVID-19 have been made available. The first five sessions are covering non-pharmaceutical countermeasures (NPC) focusing on an introduction to the topic, personal protection, environmental countermeasures, social distancing countermeasures and travel related countermeasures. The micro learning activities can be accessed via the following LINK.

European Directorate for the Quality of Medicines & HealthCare (EDQM)

Advice from the International Pharmaceutical Federation (FIP)

!NEW! FIP has divided our guidance into four sections, which assist the workforce as a whole. Guidance specifically for community, hospital and clinical biology sectors can be found in Section 2 “Guidelines for pharmacists and the pharmacy workforce”. The FIP guidance is based on the available evidence and the recommendations of reputable organisations such as the World Health Organization, the United States and the European Centres for Disease Control and Prevention, and others, as cited at the time of publishing. The available knowledge about COVID-19 is rapidly changing and such recommendations may change accordingly. Although FIP will strive to keep these guidelines up to date, they recommend consulting the websites of these organisations and any newly available evidence for the most recent updates.

NOTE: FIP is collaborating with its member organisations and other partners to make this guidance available in different languages, for maximal dissemination and use. FIP will notify their networks via their social media channels as translations are released.

FIP guidance summarised

NOTE: FIP is sharing guidance and examples from our member organisations and others below. Please note, however, that this sharing is not an endorsement of these materials and they can take no responsibility for their accuracy or their being up-to-date.

You can find more resources from FIP members here

Other FIP resources

Advice for healthcare professionals and scientists provided by different European countries

Finland

  • News about COVID-19 coronavirus | Ajankohtaista koronaviruksesta COVID-19
    The Finnish Institute for Health and Welfare has shared information about the spread of COVID-19 in Finland and the disease itself. In addition, the website contains guidelines for healthcare professionals, workplace instructions, hygiene and cough instructions as well as information for travellers and citizens.
  • Coronavirus COVID-19 – Latest Updates
    Limited information has been made available by the Finnish Institute for Health and Welfare in English on the situation in Finland, Europe and the rest of the world.

Greece

  • COVID-19 instructions | Νέος κορωνοϊός Covid-19 – Οδηγίες
    The National Public Health Organisation of Greece has put together detailed information on COVID-19. Most information is only available in Greek.
  • COVID-19 Guidelines on home isolation of suspect cases
    The National Public Health Organisation of Greece has made available guidance on home isolation in English. People who have been in contact with a suspect or confirmed COVID-19 case (i.e. family members, friends, acquaintances, healthcare workers) are advised to monitor their health condition (temperature check twice a day) for 14 days from the last exposure. It is wise to keep daily contact with healthcare professionals throughout the entire monitoring period.
  • Novel Coronavirus COVID-19 – Advice for travellers
    The travel advice presented by the National Public Health Organisation of Greece provides recommendations for travelling to or coming back from areas with local transmission of COVID-19. The information shared is available in English.

Italy

Spain

The Netherlands

  • Drug treatment options for patients admitted with COVID-19 | Medicamenteuze behandelopties bij opgenomen patiënten met COVID-19
    The National Institute for Health and the Environment of the Netherlands has published information on treatment options. In relation to these options it has been clarified that there are currently no registered medicines for the treatment of COVID-19, because no treatment results from therapeutic research have been published. Therapy advice for COVID-19 cannot (yet) be scientifically substantiated. Based on currently available data, the options presented are for patients admitted with COVID-19 due to severe disease symptoms.

Advice/information provided by healthcare professional organisations, individual hospital pharmacists and other related distribution channels

American Society for Parenteral and Enteral Nutrition (ASPEN)

American Society of Health-System Pharmacist (ASHP)

  • Assessment of Evidence for COVID-19-Related Treatments
    The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpre- tation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients
Canadian Pharmacists Association

China Law Translate

  • Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition) | An unofficial translation of the Chinese guidelines
    The content outlines the Chinese guidelines for COVID-19 including pathogenic and epidemiological characteristics, pathological changes and clinical characteristics. The webpage also includes the diagnostic criteria and the clinical classifications for the mild form, regular form, severe form and critical form in adults and children and the clinical warning signs. Furthermore, the guideline includes recommendations for treatment and the criteria for discharge and discharge notes as well as infection control.

Dutch Association of Hospital Pharmacists (NVZA)

  • Preparation of disinfectant for hand hygiene
    Paul Le Brun and Kirsten Schimmel, two Dutch hospital pharmacists, have put together information on the preparation of disinfectant for hand hygiene. The formulation was defined by the Dutch Laboratory of Pharmacists and has been translated into English. 

European Society of Cardiology (ESC)

  • Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers
    The statement declares that recent rumours in the media and on social media that ACE-I or ARB medications might increase the risk of a severe form of COVID-19 is not based on sound scientific basis. And that some studies (done on animals) suggest that such medications might have protective capabilities against lung complications in patients with COVID-19. The Council on Hypertension strongly recommends that patients continue their usual anti-hypertensive therapy.

French Resuscitation Society (SRLF)

  • Expert recommendations for the resuscitative management of patients during an outbreak of CoV2-CoVRSA | Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie à SARS-CoV2
    SRLF has made available recommendations for the resuscitative management of patients. Page 11 of the document lists specific treatment options for COVID-19, including recommendations for Remdesivir, Lopinavir/ritonavir; Chloroquine, Anticorps monoclonaux and Umifenovir. Molecules under evaluation include: Favipiravir, Nitazoxanide, Niclosamide, Prulifloxacin, Bictegravir, Nelfinavir, Tegobuvi and Atazanavir.

French Society of Clinical Pharmacy (SFPC)

  • !NEW! Useful Resources to Fight COVID-19 | Documents utiles à la prise en charge du COVID-19
    The French Society of Clinical Pharmacy (SFPC) has made available information linked to the good use of medicines and therapeutic care in their resource centre. The information is only available in French.

French Society of Pharmacology and Therapeutics

IDstewardship.com

  • Coronavirus (COVID-19) Resources For Pharmacists
    IDstewardship.com has created a webpage to provide insights and resources for pharmacists to help them manage the COVID-19 pandemic. The webpage lists general resources, treatment guidelines, including information on Remdesivir, Lopinavir/ritonavir (Kaletra, LPV/r), Chloroquine, Hydroxychloroquine (Plaquenil) and Tocilizumab (Actemra).

Italian Hospital Pharmacists

  • COVID-19 Bulletin UMPC in Italy of 12 March 2020 | COVID-19 Bulletin UMPC in Italy 12 marzo 2020
    The UPMC bulletin contains links to official information sources and details on how UPMC Italy is managing the situation.
  • COVID-19 treatment guideline | COVID-19 linee guida trattamento
    The diagram contains information on treatment options for COVID-19 taking also into account the severity index and the different therapies for the pneumonia associated with COVID-19.
  • Method of use of Tocilizumab in patients with Covid-19 | Modalità di impiego di Tocilizumab nei pazienti con COVID-19
    This guideline recommends that only patients with a high interleukin-6 value should be treated with Tocilizumab. The recommended treatment of cytokine release syndrome by intravenous infusion lasting 60 minutes and is equal to 4-8 mg/kg in patients weighing more than 30kg. Doses above 800mg per infusion are not recommended.

Italian Society of Hospital Pharmacy (SIFO)

  • Operating instruction for the preparation of master preparations based on antiretrovirals to be administered to patients who are unable to swallow solid whole forms | Istruzione Operativa per l'allestimento di preparati magistrali a base di antiretrovirali da somministrare a pazienti non in grado di deglutire forme solide intere
    SIFO and the Italian Society of Pharmacists Responsible for Preparing Medicines (SIFAP) have put together information on pharmacy preparations. In anticipation of an increase in the need to administer tablets in different forms to patients and the lack of pharmaceuticals suitable for the administration by tube both healthcare professional organisations have shared information on this subject based on available literature.
  • National SIFO Network – COVID-19 emergency | Rete nazionale SIFO - Emergenza COVID-19
    The Italian Society of Hospital Pharmacy has made available resources for its members to help them address the COVID-19 pandemic. The information is only available in Italian.

Italian Society of Infectious and Tropical Diseases (SIMIT)

Italian Society of Pharmacists Responsible for Preparing Medicines (SIFAP)

Liverpool Drug Interaction Group of the University of Liverpool, UK

  • Prescription resources and interactions of drugs with COVID-19
    The Liverpool Drug Interaction Group, in collaboration with the University Hospital of Basel (Switzerland) and the Radboud UMC (Netherlands), has produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19. The site is regularly updated. 

Spanish Society of Geriatrics and Gerontology (SEGG)

Spanish Society of Hospital Pharmacy (SEFH)

UMC Utrecht

  • COVID-19: What do we know about the treatment options | COVID-19: Wat weten we van de therapeutische opties?
    The presentation prepared by hospital pharmacists Emilie Gieling, in collaboration with Prof Dr David Burger from the Radboud UMC details known information about the treatment options of COVID-19. The document is only available in Dutch.

Information published by journals

Links to other useful resources

 

Last update: 1 April 2020